New Insights into Monocyte-Derived Macrophages in Glioblastoma

Area of Science:

• Neuro-oncology
• Immunology
• Cancer Biology

Background:

• Glioblastoma (GBM) is an aggressive brain tumor with an immunosuppressive microenvironment contributing to treatment resistance.
• Monocyte-derived macrophages (MDMs) are a major component of the GBM tumor microenvironment, promoting tumor progression.
• MDM infiltration is influenced by signaling pathways, blood-brain barrier disruption, and tumor hypoxia.

Purpose of the Study:

• To review the heterogeneity and functional diversity of macrophages in the GBM microenvironment.
• To explore therapeutic strategies targeting MDMs in glioblastoma.
• To highlight challenges and future directions in modulating MDMs for improved patient outcomes.

Main Methods:

• Review of recent technological advances in understanding macrophage heterogeneity.
• Analysis of signaling pathways and metabolic reprogramming in MDMs.
• Examination of preclinical and clinical therapeutic approaches targeting MDMs.

Main Results:

• Macrophages exhibit significant functional diversity, including hypoxia-induced, lipid-metabolizing, phagocytic, and interferon-activated subtypes.
• Therapeutic strategies include inhibiting MDM recruitment, enhancing phagocytosis, genetic engineering, and metabolic modulation.
• Combination therapies with immune checkpoint inhibitors show potential but face challenges due to macrophage adaptability.

Conclusions:

• Modulating monocyte-derived macrophages (MDMs) is crucial for overcoming immune tolerance in glioblastoma.
• Addressing the dynamic heterogeneity and adaptability of tumor-associated macrophages is essential for therapeutic success.
• Future combination therapies integrating multi-omics and spatial profiling are needed to precisely target MDMs and improve glioblastoma patient outcomes.